James Bradner, a senior physician-scientist, has been appointed president of the Novartis Institutes for BioMedical Research and a member of the company’s executive committee. He will assume the new job on 1 March 2016, succeeding Mark Fishman who is retiring.
Dr Bradner is on the faculty of the Harvard Medical School in the department of medical oncology at the Dana-Farber Cancer Institute. He is a graduate of Harvard College and the University of Chicago Medical School. He has co-authored more than 130 scientific publications and 30 US patent applications.
Novartis announced the appointment on 24 September 2015.
Copyright 2015 Evernow Publishing Ltd